Gabapentin for Post-operative Pain Control and Opioid Reduction in Scrotal Surgery: A Randomized Controlled Clinical Trial
Nahid Punjani,Jessica A Marinaro,Caroline Kang,Jonathan Gal,Brady Rippon,Rohan Jotwani,Roniel Weinberg,Peter N Schlegel,Jessica A. Marinaro,Peter N. Schlegel
DOI: https://doi.org/10.1097/ju.0000000000003884
2024-02-21
Abstract:PURPOSE: To assess the safety and efficacy of gabapentin in reducing post-operative pain among patients undergoing scrotal surgery for male infertility by conducting a randomized, double-blind, placebo-controlled trial.MATERIALS AND METHODS: In this randomized, double-blind, placebo-controlled trial, healthy men undergoing scrotal surgery with a single surgeon were randomized to receive either (1) gabapentin, 600 mg, given 2 hours pre-operatively and 300 mg, taken 3 times a day post-operatively for 3 days, or (2) inactive placebo. The primary outcome measure was difference in post-operative pain scores. Secondary outcomes included differences in opioid usage, patient satisfaction, and adverse events.RESULTS: Of 97 patients screened, 74 enrolled and underwent randomization. Of these, 4 men were lost to follow-up, and 70 were included in the final analysis (35 gabapentin, 35 placebo). Both differences in initial postoperative mean pain score (-1.14, 95% CI -2.21 to -0.08, <i>P</i> = .035) and final mean pain scores differences (-1.27, 95% CI -2.23 to -0.32, <i>P</i> = .0097) indicated lower gabapentin pain compared to placebo. There were no statistically significant differences in opioid usage, patient satisfaction, or adverse events.CONCLUSIONS: These data suggest that perioperative gabapentin results in a statistically and clinically significant decrease in pain following scrotal surgery. While there was no evidence of an impact on opioid usage or patient satisfaction, given the low risk of adverse events, it may be considered as part of a multimodal pain management strategy.
urology & nephrology